Project Grant HT94252410728
Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $988K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
- The Broad Institute, Inc. was awarded a $936,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The four-year award will fund research to define signaling pathways and effective combination therapies to improve outcomes for patients with FGFR2-driven biliary cancer. Through support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims...
- The Defense Health Agency awarded a $1,116,955 Project Grant to The Broad Institute, Inc. to identify new therapies and therapeutic targets in gastroesophageal cancer. This 3-year grant, running from August 15, 2023 to August 14, 2026, is funded through the Military Medical Research and Development program (CFDA 12.420). The Broad Institute, a non-profit biomedical and genomic research organization, will leverage its expertise in areas like genomic sequencing, data analysis, and translational...
- The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
- The Defense Health Agency awarded a $1,023,225 Project Grant under the Military Medical Research and Development program (CFDA# 12.420) to The Cleveland Clinic Foundation. The grant funds research to investigate the therapeutic relevance of targeting the anti-apoptotic Bcl-xL protein in kidney cancer. A sub-award to Harvard T.H. Chan School of Public Health will perform BH3 profiling to compare apoptotic responses in renal cell carcinomas under varied conditions, including treatment with BH3...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $499,600 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2027. The award supports research targeting the ZER1 ubiquitin ligase for the treatment of human papillomavirus-positive (HPV+) penile, anal, and vulvar cancers. This research initiative falls within the Defense Health Agency's portfolio of...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology in Boston, Massachusetts, received a $178,999 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective May 15, 2025, with a completion date of May 14, 2026. The award supports research focused on targeting TFE3 fusion proteins using PROTAC (proteolysis-targeting chimera) technology in...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
- The Department of the Army Medical Command awarded a $1,290,500 Project Grant to Dana-Farber Cancer Institute, Inc. to support research titled "CIRCULATING BIOMARKERS IN RENAL CELL CARCINOMA" under the Military Medical Research and Development program (CFDA 12.420). The four-year award beginning September 1, 2022 will fund research to investigate circulating biomarkers in renal cell carcinoma. The Military Medical Research and Development program aims to transform military and public...